Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. - Wikidata - awgldk - TriplyDB

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

http://www.wikidata.org/entity/Q41349219

about

Evaluation of current cancer immunotherapy: hemato-oncology Molecular analysis of immunoglobulin genes in multiple myeloma.Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.Novel immunotherapies Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Dendritic cells and immunotherapy for malignant disease.Vaccine therapy of B cell malignancies: different strategies for a novel approach.Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.Immunotherapy in multiple myeloma: current strategies and future prospects.Anti-idiotype vaccines.Dendritic cells and their potential therapeutic role in haematological malignancy.Molecular monitoring of minimal residual disease in patients with multiple myeloma.Stem cell transplantation for multiple myeloma.The role of idiotype vaccines in the treatment of human B-cell malignancies.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myeloma Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.Role of allogeneic stem cell transplantation in multiple myeloma.Immunotherapy in multiple myeloma--possibility or probability?Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor.Idiotype vaccines for lymphoma therapy.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.

P2860

Q27006179-4B96B534-CF00-4ADA-9C0C-EE84FE3D15FF Q33604355-20D9C339-086A-4491-9EBE-1F674E5CA795 Q33762537-31BFB1EB-F440-4C54-9B33-95A15EBA934C Q33822677-9C819407-1F0D-4748-A8AB-927626EB907F Q33895386-216F041B-034B-4965-99C8-7C65E0DB3493 Q33994342-3161450C-5521-401B-AA60-217874799E24 Q34011489-CDCA0D0F-B4C3-4653-BFBD-0991FEAE532E Q34065058-D40E9731-570E-49C5-ADF2-17F1A5009D04 Q34124707-CEB642A2-8F4F-40BD-9A80-1DB316BE5F2F Q34202277-34B73338-364C-44EB-86C2-E4FFB19D4DE2 Q34216506-48CD967C-29F0-443A-AB40-B81CA2B3A867 Q34430359-5B39AD03-76F9-4B4F-AE51-8AC28B20EF27 Q34463419-499BC958-D345-42C4-AA86-BC2E46FB331A Q34487409-846EC2D5-4879-4E52-B591-1BE8CEC5B2F5 Q34734310-4CD64C88-D8A8-40FF-B673-B3F0D3175DBC Q35079386-395DF39B-510B-46D8-ACE6-AD9B22FCBAA7 Q35122185-0B7F22B7-F295-41E9-8921-A9C19DF3EE96 Q35194182-B542F002-1BAF-4233-92FF-87C23CFA3DB9 Q35591089-F04F3144-12DE-46CB-B9B6-A4BFFC243582 Q35614625-30AA5EC2-B6D5-4095-B945-C648E4121842 Q35668677-30964512-3C14-449B-BBDE-D538542BEE22 Q35692626-422A4BAC-CD46-4689-A520-DE7A7EA30F74 Q35728597-97209F62-83B0-4141-BD33-08B9F9B50B26 Q35852574-2999386D-1706-4239-AE8A-8C6839BD5B30 Q35865581-76BFF72F-561C-4FEC-BA66-62741AC92FAB Q35884710-8B210009-E955-44D4-8477-E8B37B5E1E17 Q35918466-83E71B03-FA49-44DC-9E31-03689EE94E68 Q36185617-CCD52A41-5F16-467E-AE61-094531C856F7 Q36206601-3843B187-8754-412A-9693-7E556C4C24F8 Q36312922-1BA7FB68-A8F3-4C18-B509-8E896BEE76E5 Q36487595-16615C39-E705-460B-BC5F-83AA2CA6538B Q36689152-C011B2E2-BC20-4081-BE1D-13ADC804540F Q36819337-1114B85C-09FD-4B95-B8C7-320206F65074 Q36849339-651495E5-CB94-4D17-8328-567BF7F635E5 Q37305644-84BE7529-8407-43A7-BFE4-47CCD9C28817 Q37401011-1E322235-595D-4ABB-95BE-8545A99F7FEC Q37445265-F78623E1-1B99-4A5F-8516-66135EBF9108 Q37460362-80ACD48E-E938-43DC-B0D9-718CD8CA8508 Q37892587-2186D6D4-D194-4550-A6A5-D5AC9F3B410F Q38195065-135C9864-5CF8-4C09-BCDF-52504113978C

P2860

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

http://www.wikidata.org/entity/Q41349219

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

1995年论文

@zh

1995年论文

@zh-cn

name

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

@en

type

label

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

@en

prefLabel

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

@en

P1433

Q41349219-92E66B39-DA7C-4D75-85DA-D10A4171133D

P1476

Q41349219-928F8D48-190E-4137-8250-566AFDCBEA46

P2093

Q41349219-16580B16-FE98-4CCF-BFE8-CBF4B22E00D0

Q41349219-2CA75555-2468-4056-802B-0B4C86C01887

Q41349219-5715E553-52C4-450B-A4EA-7C5365E5B242

Q41349219-AAFFD6C4-1F24-48D6-AA81-4EF7CD264AB9

Q41349219-AE8EB933-3716-4070-B862-8DAC16E0BD00

Q41349219-E2AE3581-58DD-4CDE-BE92-2FBE4D92084A

Q41349219-EFA8B84F-45A5-41A6-9389-C4F6F12177C9

P304

Q41349219-6C18820A-788C-4F8E-92CC-C1AC73F019CB

P31

Q41349219-001DD9A5-92B8-474A-A5A6-4695C3D5BCB5

P356

Q41349219-FCA4EAFA-FC52-443A-AE0D-9D99FF2528BC

P407

Q41349219-044FE005-5E64-4013-B448-06E79C7B65C2

P433

Q41349219-BC279D55-14FE-4008-BE27-5887CCFE5261

P478

Q41349219-C71DBFC4-A472-4860-9169-44C5BA340382

P577

Q41349219-ED4AF6CD-23CC-4C8B-907A-139C6B3009B6

P698

Q41349219-DC981665-B298-4F4A-B6B6-E0C27ABC7D19

P356

S0140-6736(95)90757-2

P1433

P1476

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

@en

P2093

C W Reynolds

http://www.w3.org/2001/XMLSchema#string

D D Taub

http://www.w3.org/2001/XMLSchema#string

D L Longo

http://www.w3.org/2001/XMLSchema#string

E M Bryant

http://www.w3.org/2001/XMLSchema#string

L W Kwak

http://www.w3.org/2001/XMLSchema#string

P L Duffey

http://www.w3.org/2001/XMLSchema#string

W I Bensinger

http://www.w3.org/2001/XMLSchema#string

P304

1016-1020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(95)90757-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

8956

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P577

1995-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7723498

http://www.w3.org/2001/XMLSchema#string